Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 545Lymphoma 444Precursor Cell Lymphoblastic Leukemia-Lymphoma 409Lymphoma, Large B-Cell, Diffuse 347Leukemia 344Multiple Myeloma 335Lymphoma, Non-Hodgkin 316Leukemia, Myeloid, Acute 288Leukemia, Lymphocytic, Chronic, B-Cell 285Lymphoma, Follicular 240Burkitt Lymphoma 217Myelodysplastic Syndromes 209Lymphoma, Mantle-Cell 201Hodgkin Disease 193Recurrence 153Lymphoma, B-Cell, Marginal Zone 142Melanoma 135Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 96Triple Negative Breast Neoplasms 93Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

Sirolimus 4LY3295668 erbumine 3Everolimus 3Anticonvulsants 2perampanel 1clevidipine 1brivaracetam 1Vigabatrin 1Topotecan 1Therapeutic Touch 1Temozolomide 1TAS-119 1Sulfasalazine 1Sevoflurane 1Saline Solution 1Radiotherapy 1Propofol 1Paclitaxel 1Nitrous Oxide 1Midazolam 1Memantine 1Medical Marijuana 1Lidocaine 1Levetiracetam 1Ketamine 1Immunoglobulins, Intravenous 1Glycopyrrolate 1Gabapentin 1Fluid Therapy 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Epilepsy × Cyclophosphamide × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡